CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion

World Journal of Surgical Oncology

Shailesh Singh¹  James W Lillard¹  William E Grizzle²  Erica L Johnson¹  Rajesh Singh¹  Crystal Johnson-Holiday¹ 

[1] Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310 USA;Department of Pathology, University of Alabama at Birmingham, West Pavilion P220 619 South 19th Street, Birmingham, AL 35233 USA

关键词: cisplatin resistance;    CCL25;    CCR9;    breast cancer;    chemokine;   

Others  :  1206719
DOI  :  10.1186/1477-7819-9-46

 received in 2010-09-25, accepted in 2011-05-03,  发布年份 2011

【 摘 要 】

Background

Chemotherapy heavily relies on apoptosis to kill breast cancer (BrCa) cells. Many breast tumors respond to chemotherapy, but cells that survive this initial response gain resistance to subsequent treatments. This leads to aggressive cell variants with an enhanced ability to migrate, invade and survive at secondary sites. Metastasis and chemoresistance are responsible for most cancer-related deaths; hence, therapies designed to minimize both are greatly needed. We have recently shown that CCR9-CCL25 interactions promote BrCa cell migration and invasion, while others have shown that this axis play important role in T cell survival. In this study we have shown potential role of CCR9-CCL25 axis in breast cancer cell survival and therapeutic efficacy of cisplatin.

Methods

Bromodeoxyuridine (BrdU) incorporation, Vybrant apoptosis and TUNEL assays were performed to ascertain the role of CCR9-CCL25 axis in cisplatin-induced apoptosis of BrCa cells. Fast Activated Cell-based ELISA (FACE) assay was used to quantify In situ activation of PI3K^p85, Akt^Ser473, GSK-3β^Ser9 and FKHR^Thr24 in breast cancer cells with or without cisplatin treatment in presence or absence of CCL25.

Results

CCR9-CCL25 axis provides survival advantage to BrCa cells and inhibits cisplatin-induced apoptosis in a PI3K-dependent and focal adhesion kinase (FAK)-independent fashion. Furthermore, CCR9-CCL25 axis activates cell-survival signals through Akt and subsequent glycogen synthase kinase-3 beta (GSK-3β) and forkhead in human rhabdomyosarcoma (FKHR) inactivation. These results show that CCR9-CCL25 axis play important role in BrCa cell survival and low chemotherapeutic efficacy of cisplatin primarily through PI3K/Akt dependent fashion.

【 授权许可】

   
2011 Johnson-Holiday et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
• [2]Thomadaki H, Scorilas A: Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci 2007, 1095:35-44.
• [3]Simstein R, Burow M, Parker A, Weldon C, Beckman B: Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 2003, 228:995-1003.
• [4]Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
• [5]Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW Jr: Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion. Clin Cancer Res 2004, 10:8743-8750.
• [6]Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW, Singh S: CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res 2010, 3:15. BioMed Central Full Text
• [7]Uehara S, Grinberg A, Farber JM, Love PE: A role for CCR9 in T lymphocyte development and migration. J Immunol 2002, 168:2811-2819.
• [8]Wurbel MA, Philippe JM, Nguyen C, Victorero G, Freeman T, Wooding P, Miazek A, Mattei MG, Malissen M, Jordan BR, et al.: The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol 2000, 30:262-271.
• [9]Aoki K, Ogawa T, Ito Y, Nakashima S: Cisplatin activates survival signals in UM- SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma. Oncol Rep 2004, 11:375-379.
• [10]Sonoda E, Matsumoto R, Hitoshi Y, Ishii T, Sugimoto M, Araki S, Tominaga A, Yamaguchi N, Takatsu K: Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med 1989, 170:1415-1420.
• [11]Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C: Breast cancer genetics in African Americans. Cancer 2003, 97:236-245.
• [12]Giai M, Biglia N, Sismondi P: Chemoresistance in breast tumors. Eur J Gynaecol Oncol 1991, 12:359-373.
• [13]Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997, 71:787-795.
• [14]Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ: AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 2003, 278:23432-23440.
• [15]Yde CW, Issinger OG: Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J Oncol 2006, 29:1397-1404.
• [16]Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J: Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007, 6:1869-1876.
• [17]Smith L, Welham KJ, Watson MB, Drew PJ, Lind MJ, Cawkwell L: The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res 2007, 16:497-506.
• [18]Buolamwini JK: Novel anticancer drug discovery. Curr Opin Chem Biol 1999, 3:500-509.
• [19]Gomperts BN, Strieter RM: Chemokine-directed metastasis. Contrib Microbiol 2006, 13:170-190.
• [20]Moore MA: The role of chemoattraction in cancer metastases. Bioessays 2001, 23:674-676.
• [21]Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya CV: G Protein-Coupled Chemokine Receptors Induce Both Survival and Apoptotic Signaling Pathways. J Immunol 2002, 169:5546-5554.
• [22]Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, Mantovani A, Allavena P: Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004, 64:8420-8427.
• [23]Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G: Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clinical Cancer Research 2005, 11:1835-1841.
• [24]Wurbel MA, Malissen M, Guy-Grand D, Meffre E, Nussenzweig MC, Richelme M, Carrier A, Malissen B: Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial lymphocytes. Blood 2001, 98:2626-2632.
• [25]Singh S, Singh UP, Grizzle WE, Lillard JW: CXCL12-CXCR4 interactions modulates prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004, 84:1666-1676.
• [26]Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, Maroni P, Donohue R, Meacham RB, Koul HK: Focal Adhesion Kinase Controls Aggressive Phenotype of Androgen-Independent Prostate Cancer. Mol Cancer Res 2008, 6:1639-1648.
• [27]Youn BS, Yu KY, Oh J, Lee J, Lee TH, Broxmeyer HE: Role of the CC chemokine receptor 9/TECK interaction in apoptosis. Apoptosis 2002, 7:271-276.
• [28]Sotsios Y, Ward SG: Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines. Immunological Reviews 2000, 177:217.
• [29]Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193-204.
• [30]Tilton B, Ho L, Oberlin E, Loetscher P, Baleux F, Clark-Lewis I, Thelen M: Signal transduction by CXC chemokine receptor 4. Stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes. J Exp Med 2000, 192:313-324.
• [31]Li L, Ren CH, Tahir SA, Ren C, Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003, 23:9389-9404.
• [32]McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC: The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005, 5:505-515.
• [33]Kwong L, Wozniak MA, Collins AS, Wilson SD, Keely PJ: R-Ras promotes focal adhesion formation through focal adhesion kinase and p130(Cas) by a novel mechanism that differs from integrins. Mol Cell Biol 2003, 23:933-949.
• [34]Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD: Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 2008, 283:739-750.